Assoc. Prof. Dr. Muhammet Özbilen is a specialist in internal medicine at Ordu University Faculty of Medicine, Training and Research Hospital in Turkey. His primary research interests center on iron deficiency, with a particular focus on intravenous iron preparations, overlooked causes of iron defiency and underreported clinical manifestations.
Dr. Özbilen has made notable contributions to the field by identifying and describing “geosminophilia”—a newly proposed symptom of iron deficiency characterized by an unusual craving for the smell of earth—as a potential clinical clue to diagnosis. In addition, he co-authored the first clinical description of methemoglobinemia as an adverse effect of ferric carboxymaltose, expanding current knowledge about the safety profile of intravenous iron therapies.
He currently coordinates a multicenter clinical trial (NCT06958822) investigating the incidence and clinical relevance of ferric carboxymaltose–induced methemoglobinemia.
Dr. Özbilen is also actively engaged in medical education, mentoring medical students and residents, and contributing to the integration of clinical research into daily practice. His ongoing work continues to shape a deeper understanding of iron metabolism disorders and their systemic implications.
Assoc. Prof. Dr. Muhammet Özbilen is a specialist in internal medicine at Ordu University Faculty of Medicine, Training and Research Hospital in Turkey. His primary research interests center on iron deficiency, with a particular focus on intravenous iron preparations, overlooked causes of iron defiency and underreported clinical manifestations.
Dr. Özbilen has made notable contributions to the field by identifying and describing “geosminophilia”—a newly proposed symptom of iron deficiency characterized by an unusual craving for the smell of earth—as a potential clinical clue to diagnosis. In addition, he co-authored the first clinical description of methemoglobinemia as an adverse effect of ferric carboxymaltose, expanding current knowledge about the safety profile of intravenous iron therapies.
He currently coordinates a multicenter clinical trial (NCT06958822) investigating the incidence and clinical relevance of ferric carboxymaltose–induced methemoglobinemia.
Dr. Özbilen is also actively engaged in medical education, mentoring medical students and residents, and contributing to the integration of clinical research into daily practice. His ongoing work continues to shape a deeper understanding of iron metabolism disorders and their systemic implications.